CRYSTAGEN 20MG

Crystagen 20mg is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Pro (EDP), developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Identified as one of the principal bioactive components of Thymalin — the bovine thymus extract approved in Russia since 1982 — Crystagen is the isolated and synthetically reproduced active immunomodulatory fraction, studied for its broad-spectrum regulatory activity across T-lymphocyte populations, B-cell populations, thymic epithelial cells, and immune cell networks throughout the spleen and bone marrow.

At approximately 345 Da, Crystagen is among the smallest molecular weight compounds in the Khavinson family, facilitating direct nuclear membrane penetration in immune cell populations. Research has examined its proposed epigenetic mechanism of chromatin decondensation in immunocompetent cells, modulation of heat-shock protein (HSP) gene expression, cytokine regulation, and selective activity on lymphocyte proliferation — enhancing normal lymphocyte proliferative activity while inhibiting tumor cell growth in K-562 erythromyelosis models. Published data reports immune normalization in 82% of elderly patients studied versus 56% in control groups, representing one of the strongest human-referenced outcome datasets in the Khavinson bioregulator literature.

Beyond Health Lab supplies Crystagen 20mg as a research-grade lyophilized compound, HPLC-verified for 99% purity, shipped within 24 hours from Mexico.

For research use only. Not intended for human or animal consumption.

FAQ:

What is Crystagen and how does it relate to Thymalin and Thymogen?
Crystagen (Glu-Asp-Pro / EDP) is a synthetic tripeptide identified as one of the principal active components of Thymalin, the thymus extract approved in Russia since 1982. While Thymalin contains a complex mixture of thymic peptides, Crystagen is the isolated EDP fraction — enabling more controlled, reproducible immune research designs. It differs from Thymogen (Glu-Trp dipeptide), which primarily targets T-cell differentiation pathways. Crystagen is studied for broader systemic immune activity across T-cell, B-cell, thymic epithelial, spleen, and bone marrow cell populations — making it the more comprehensive immune bioregulator of the two.

What immune cell mechanisms and gene targets has Crystagen been studied for?
Research has examined Crystagen’s effects on spontaneous T-lymphocyte and B-lymphocyte proliferation, thymic epithelial cell activity, heat-shock protein (HSP) gene expression regulation, pro-inflammatory and regulatory cytokine modulation, and differential effects on normal versus tumor cell proliferation — specifically demonstrating inhibition of K-562 erythromyelosis tumor cell growth while simultaneously enhancing normal lymphocyte activity. Its mechanism involves chromatin decondensation in immunocompetent cells, restoring gene expression programs silenced by aging-related DNA condensation.

What published outcome data exists for Crystagen in immune aging research?
Published research reports immune function normalization in 82% of elderly subjects studied with Crystagen versus 56% in control groups — one of the strongest human-referenced outcome datasets among Khavinson bioregulators. Additional studies have examined respiratory infection reduction in athletic populations through HSP gene expression upregulation, and immune recovery in post-chemotherapy and post-radiation exposure models. Key reference: Peptide Database (Khavinson group publications) and PeptideInsight evidence review (2026).

How should Crystagen 20mg be stored?
Store lyophilized Crystagen at 2–8°C away from light and moisture. Once reconstituted with bacteriostatic water, keep refrigerated and use within 28 days for optimal stability and research-grade performance.